<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986881</url>
  </required_header>
  <id_info>
    <org_study_id>8835-004</org_study_id>
    <secondary_id>2013-002518-11</secondary_id>
    <secondary_id>B1521021</secondary_id>
    <nct_id>NCT01986881</nct_id>
  </id_info>
  <brief_title>Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An overall study of the cardiovascular outcomes following treatment with ertugliflozin in&#xD;
      participants with type 2 diabetes mellitus (T2DM) and established vascular disease. The main&#xD;
      objective of this study is to assess the cardiovascular safety of ertugliflozin. This trial&#xD;
      includes 3 pre-defined glycemic sub-studies; 1. In participants receiving background insulin&#xD;
      with or without metformin, 2. In participants receiving background sulfonylurea monotherapy,&#xD;
      and 3. In participants receiving background metformin with sulfonylurea (all fully-enrolled).&#xD;
&#xD;
      Participants enrolled prior to Amendment 1 were in the overall study as well as a sub-study,&#xD;
      if they met certain entry criteria. Participants enrolled following the start of Amendment 1&#xD;
      were only enrolled in the overall study. The sub-studies were the initial 18 weeks of the&#xD;
      overall study period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypotheses for the 4 studies are:&#xD;
&#xD;
        1. Overall Cardiovascular Study:&#xD;
&#xD;
           The time to first occurrence of the composite endpoint of MACE: cardiovascular death,&#xD;
           non-fatal myocardial infarction [MI] or non-fatal stroke in participants treated with&#xD;
           ertugliflozin is non-inferior compared to that in participants treated with placebo.&#xD;
&#xD;
        2. The 3 Glycemic Sub-studies:&#xD;
&#xD;
             1. The mean reduction from baseline in hemoglobin A1c (A1C) for 15 mg ertugliflozin is&#xD;
                greater than that for placebo.&#xD;
&#xD;
             2. The mean reduction from baseline in A1C for 5 mg ertugliflozin is greater than that&#xD;
                for placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2013</start_date>
  <completion_date type="Actual">December 27, 2019</completion_date>
  <primary_completion_date type="Actual">December 27, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke. The on-treatment approach included confirmed events that occurred between the date of first dose of study medication and the on-treatment censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or 365 days after the last dose).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</measure>
    <time_frame>Baseline</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects Week 0 A1C.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of Cardiovascular (CV) Death or Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Time to the occurrence of any of the following adjudicated components of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)) or hospitalization for heart failure. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of Cardiovascular Death (On-study Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Time to the occurrence of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to CV death or time to censoring (the earliest of participants' end of study date or date last known to be alive).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of the Renal Composite: the Composite of Renal Death, Renal Dialysis/Transplant, or Doubling of Serum Creatinine From Baseline (On-Study Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Renal composite endpoint was defined as a composite of renal death, renal dialysis/transplant, or doubling of serum creatinine from baseline. The on-study approach included events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of MACE Plus (Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke or Hospitalization for Unstable Angina) (On-Study Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Time to the first occurrence of any of the following adjudicated components 4-point MACE: cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina pectoris. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction (On-Study Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Fatal or Non-fatal Stroke (FNF Stroke) (On-Study Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Time to the first occurrence of fatal and no-fatal stroke. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Occurrence of Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Time to the first occurrence of heart failure requiring hospitalization (adjudicated). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of Death From Any Cause (On-Study Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Time to the occurrence of death from any cause. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or date last known to be alive. The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Andersen-Gill Model for Total MACE (On-Study Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>All events (first and recurrent) of the composite of MACE (3-point major adverse cardiovascular events: cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke) were assessed using Andersen-Gill model. The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Andersen-Gill Model for All Cardiovascular Death (CV Death) or Hospitalizations for Heart Failure (HFF) (On-Study Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>All events (first and recurrent) of the composite of CV death and HHF were assessed using an Andersen-Gill model. Person-years were calculated as the sum of time from randomization to end of follow-up. The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 24 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 36 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 48</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 48 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 60 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in A1C at Month 72 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 72</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 72 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Overall Cardiovascular Study)</measure>
    <time_frame>Week 18</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Week 52</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 24</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 36</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 48</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 60</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Week 18 (Overall Cardiovascular Study)</measure>
    <time_frame>Week 18</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Week 52</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 24</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 36</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 48</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 60</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding rescue&quot;, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 52 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 24 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 36 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 48</time_frame>
    <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 48 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 60 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 72 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 72</time_frame>
    <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 72 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First Occurrence of a Participant Receiving Glycemic Rescue Therapy Through Week 18 (Overall Cardiovascular Study)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Initiation of Insulin for Participants Not on Insulin at Baseline (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>Participants who were not on insulin therapy at the start of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Insulin Dose for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline reflects Week 0 insulin dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Dose at Week 18 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Dose at Week 52 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>This change from baseline reflects the Week 52 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Dose at Month 24 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>This change from baseline reflects the Month 24 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Dose at Month 36 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>This change from baseline reflects the Month 36 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Dose at Month 48 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 48</time_frame>
    <description>This change from baseline reflects the Month 48 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Dose at Month 60 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>This change from baseline reflects the Month 60 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding rescue&quot;, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>This change from baseline reflects the Week 52 sitting SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>This change from baseline reflects the Month 24 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>This change from baseline reflects the Month 36 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 48</time_frame>
    <description>This change from baseline reflects the Month 48 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>This change from baseline reflects the Month 60 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 72 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 72</time_frame>
    <description>This change from baseline reflects the Month 72 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding rescue&quot;, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>This change from baseline reflects the Week 52 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>This change from baseline reflects the Month 24 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>This change from baseline reflects the Month 36 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 48</time_frame>
    <description>This change from baseline reflects the Month 48 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>This change from baseline reflects the Month 60 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 72 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 72</time_frame>
    <description>This change from baseline reflects the Month 72 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>This change from baseline reflects the Month 24 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>This change from baseline reflects the Month 36 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 48</time_frame>
    <description>This change from baseline reflects the Month 48 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>This change from baseline reflects the Month 60 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Month 72 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 72</time_frame>
    <description>This change from baseline reflects the Month 72 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 18 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>This change from baseline reflects the Week 52 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>This change from baseline reflects the Month 24 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>This change from baseline reflects the Month 36 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 48</time_frame>
    <description>This change from baseline reflects the Month 48 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>This change from baseline reflects the Month 60 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 72 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 72</time_frame>
    <description>This change from baseline reflects the Month 72 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Serum Creatinine (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline reflects Week 0 serum creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Week 18 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>This change from baseline reflects the Week 52 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>This change from baseline reflects the Month 24 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>This change from baseline reflects the Month 36 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 48</time_frame>
    <description>This change from baseline reflects the Month 48 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>This change from baseline reflects the Month 60 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Creatinine at Month 72 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 72</time_frame>
    <description>This change from baseline reflects the Month 72 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Urinary Albumin/Creatinine Ratio (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline reflects Week 0 albumin/creatinine ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 18 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This percent change relative to baseline reflects the Week 18 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>This percent change relative to baseline reflects the Week 52 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>This percent change relative to baseline reflects the Month 24 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>This percent change relative to baseline reflects the Month 36 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 48</time_frame>
    <description>This percent change relative to baseline reflects the Month 48 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Baseline and Month 60</time_frame>
    <description>This percent change relative to baseline reflects the Month 60 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Albuminuria Progression or Regression at Week 18 (Overall Cardiovascular Study)</measure>
    <time_frame>Week 18</time_frame>
    <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal-albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Albuminuria Progression or Regression at Week 52 (Overall Cardiovascular Study)</measure>
    <time_frame>Week 52</time_frame>
    <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Albuminuria Progression or Regression at Month 24 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 24</time_frame>
    <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Albuminuria Progression or Regression at Month 36 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 36</time_frame>
    <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Albuminuria Progression or Regression at Month 48 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 48</time_frame>
    <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline and normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Albuminuria Progression or Regression at Month 60 (Overall Cardiovascular Study)</measure>
    <time_frame>Month 60</time_frame>
    <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing an Adverse Event (AE) (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing an Adverse Event (AE) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing an Adverse Event (AE) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing an Adverse Event (AE) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Study Treatment Due to An AE (Overall Cardiovascular Study)</measure>
    <time_frame>Up to approximately 6 years</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Study Treatment Due to An AE (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Study Treatment Due to An AE (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Discontinuing Study Treatment Due to An AE (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in the FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Week 18</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 DBP minus the Week 0 BBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Insulin Dose for Participants Receiving Insulin at Baseline - (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline reflects Week 0 insulin dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at Week 18 in Insulin Dose for Participants Receiving Insulin at Baseline - Including Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a decrease in insulin dose. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Including rescue&quot;, included data following the initiation of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</measure>
    <time_frame>Week 18</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</measure>
    <time_frame>Week 18</time_frame>
    <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</measure>
    <time_frame>Baseline and Week 18</time_frame>
    <description>This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8246</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin, 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 15 mg administered orally once daily for up to approximately 6 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin, 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg administered orally once daily for up to approximately 6 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to ertugliflozin administered orally once daily for up to approximately 6 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin</intervention_name>
    <description>Oral, once daily, for up to approximately 6 years</description>
    <arm_group_label>Ertugliflozin, 15 mg</arm_group_label>
    <arm_group_label>Ertugliflozin, 5 mg</arm_group_label>
    <other_name>MK-8835, PF-04971729, Steglatro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
    <arm_group_label>Ertugliflozin, 5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycemic Rescue</intervention_name>
    <description>Doses of background anti-hyperglycemic agents (AHA), medications will be required to be held constant in all participants enrolled for the initial 18 weeks of the trial with 2 exceptions: First, participant will be prescribed glycemic rescue therapy if they meet specific, progressively more stringent, glycemic thresholds based on repeated, confirmed fasting plasma glucose (FPG) measured at a central laboratory. Second, a participant experiencing clinically significant hypoglycemia according to the investigator at any time during the trial is permitted to have the dose of appropriate background AHA (e.g., insulin, sulfonylurea [SU], glinide) reduced or discontinued as per the judgment of the investigator or the treating physician. Choice and dosing of glycemic rescue will be at the discretion of the investigator or the treating physician consistent with standards of care for management of patients with Type 2 diabetes mellitus (T2DM) within the country of the investigational site.</description>
    <arm_group_label>Ertugliflozin, 15 mg</arm_group_label>
    <arm_group_label>Ertugliflozin, 5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Overall Cardiovascular Study):&#xD;
&#xD;
          -  Diagnosis of T2DM in accordance with American Diabetes Association (ADA) guidelines&#xD;
&#xD;
          -  Hemoglobin A1c (A1C) at the start of study participation of 7.0-10.5% (53-91 mmol/mol)&#xD;
&#xD;
          -  On stable allowable anti-hyperglycemic agents (AHA) or on no background AHA for at&#xD;
             least 8 weeks prior to the study participation&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; or = to 18.0 kg/m^2&#xD;
&#xD;
          -  Evidence or a history of atherosclerosis involving the coronary, cerebral or&#xD;
             peripheral vascular systems&#xD;
&#xD;
          -  There is adequate documentation of the objective evidence that the participant has&#xD;
             established vascular disease such as investigational site's medical records, copies of&#xD;
             such records from other institutions, or a letter from a referring physician that&#xD;
             specifically states the diagnosis and date of the most recent occurrence of the&#xD;
             qualifying event(s) or procedure(s).&#xD;
&#xD;
          -  Male, female not or reproductive potential, or female of reproductive potential who&#xD;
             agrees to be abstinent from heterosexual activity or agrees to use or have their&#xD;
             partner use 2 acceptable methods of contraception&#xD;
&#xD;
        Exclusion Criteria (Overall Cardiovascular Study):&#xD;
&#xD;
          -  Previous randomization into this trial&#xD;
&#xD;
          -  Experiencing a cardiovascular event (myocardial infarction or stroke) or undergoing&#xD;
             coronary angioplasty or peripheral intervention procedure between the Screening Visit&#xD;
             and randomization&#xD;
&#xD;
          -  Undergoing any cardiovascular surgery (valvular surgery) within 3 months of study&#xD;
             participation&#xD;
&#xD;
          -  Planned revascularization or peripheral intervention procedure or other cardiovascular&#xD;
             surgery&#xD;
&#xD;
          -  New York Heart Association (NYHA) IV heart failure at study participation&#xD;
&#xD;
          -  History of type 1 diabetes mellitus or a history of ketoacidosis&#xD;
&#xD;
        Key Inclusion Criteria for the 3 Glycemic Sub-studies:&#xD;
&#xD;
          1. Insulin With or Without Metformin Sub-study: Stable doses of insulin (&gt;=20 units/day,&#xD;
             with variations up to 10% in the daily dose permitted) with or without metformin&#xD;
             (&gt;=1500 mg/day) for at least 8 weeks prior to the time of the Screening Visit (V1) and&#xD;
             during the period between the Screening Visit (V1) and randomization.&#xD;
&#xD;
          2. Sulfonylurea (SU) Monotherapy Sub-study: Participants receiving a stable dose of SU&#xD;
             monotherapy for at least 8 weeks prior to the time of the Screening Visit (V1) and&#xD;
             during the period between the Screening Visit (V1) and randomization.&#xD;
&#xD;
          3. Metformin with SU Sub-study: Participants receiving a stable dose metformin (1500&#xD;
             mg/day) with a SU for at least 8 weeks prior to the time of the Screening Visit (V1)&#xD;
             and during the period between the Screening Visit (V1) and randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>Georgia</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG; VERTIS-CV Investigators. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018 Dec;206:11-23. doi: 10.1016/j.ahj.2018.08.016. Epub 2018 Sep 5.</citation>
    <PMID>30290289</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <results_first_submitted>December 16, 2020</results_first_submitted>
  <results_first_submitted_qc>January 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2021</results_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertugliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT01986881/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT01986881/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study included participants in 34 countries at 548 study centers (Overall Cardiovascular Study).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
          <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
        </group>
        <group group_id="P2">
          <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
          <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Overall Cardiovascular Study)</title>
          <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2752"/>
                <participants group_id="P2" count="2747"/>
                <participants group_id="P3" count="2747"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="2746"/>
                <participants group_id="P2" count="2747"/>
                <participants group_id="P3" count="2745"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Enrolled in the Insulin +/- Metformin Glycemic Sub-Study</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
                <participants group_id="P2" count="370"/>
                <participants group_id="P3" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Enrolled in the Sulfonylurea Monotherapy Glycemic Sub-Study</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Enrolled in the Metformin With Sulfonylurea Glycemic Sub-Study</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2422"/>
                <participants group_id="P2" count="2401"/>
                <participants group_id="P3" count="2389"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="330"/>
                <participants group_id="P2" count="346"/>
                <participants group_id="P3" count="358"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="247"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Site Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population is all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
          <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
        </group>
        <group group_id="B2">
          <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
          <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Overall Cardiovascular Study)</title>
          <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2752"/>
            <count group_id="B2" value="2747"/>
            <count group_id="B3" value="2747"/>
            <count group_id="B4" value="8246"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2752"/>
                    <count group_id="B2" value="2747"/>
                    <count group_id="B3" value="2747"/>
                    <count group_id="B4" value="8246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="8.2"/>
                    <measurement group_id="B2" value="64.4" spread="8.0"/>
                    <measurement group_id="B3" value="64.4" spread="8.0"/>
                    <measurement group_id="B4" value="64.4" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2752"/>
                    <count group_id="B2" value="2747"/>
                    <count group_id="B3" value="2747"/>
                    <count group_id="B4" value="8246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="801"/>
                    <measurement group_id="B2" value="832"/>
                    <measurement group_id="B3" value="844"/>
                    <measurement group_id="B4" value="2477"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1951"/>
                    <measurement group_id="B2" value="1915"/>
                    <measurement group_id="B3" value="1903"/>
                    <measurement group_id="B4" value="5769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2752"/>
                    <count group_id="B2" value="2747"/>
                    <count group_id="B3" value="2747"/>
                    <count group_id="B4" value="8246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="353"/>
                    <measurement group_id="B2" value="347"/>
                    <measurement group_id="B3" value="343"/>
                    <measurement group_id="B4" value="1043"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2390"/>
                    <measurement group_id="B2" value="2392"/>
                    <measurement group_id="B3" value="2399"/>
                    <measurement group_id="B4" value="7181"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2752"/>
                    <count group_id="B2" value="2747"/>
                    <count group_id="B3" value="2747"/>
                    <count group_id="B4" value="8246"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="162"/>
                    <measurement group_id="B4" value="498"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="235"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2390"/>
                    <measurement group_id="B2" value="2436"/>
                    <measurement group_id="B3" value="2414"/>
                    <measurement group_id="B4" value="7240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="206"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <population>The analysis population included all participants with an baseline FPG measurement.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2739"/>
                    <count group_id="B2" value="2737"/>
                    <count group_id="B3" value="2727"/>
                    <count group_id="B4" value="8203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176.1" spread="52.5"/>
                    <measurement group_id="B2" value="174.8" spread="51.6"/>
                    <measurement group_id="B3" value="173.6" spread="49.4"/>
                    <measurement group_id="B4" value="174.8" spread="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sitting Systolic Blood Pressure (SBP)</title>
          <population>The analysis population included all participants with a baseline SBP measurement.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2740"/>
                    <count group_id="B2" value="2741"/>
                    <count group_id="B3" value="2740"/>
                    <count group_id="B4" value="8221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.7" spread="13.7"/>
                    <measurement group_id="B2" value="133.2" spread="13.8"/>
                    <measurement group_id="B3" value="133.1" spread="13.9"/>
                    <measurement group_id="B4" value="133.3" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sitting Diastolic Blood Pressure (DBP)</title>
          <population>The analysis population included all participants with a baseline DBP measurement.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2740"/>
                    <count group_id="B2" value="2741"/>
                    <count group_id="B3" value="2740"/>
                    <count group_id="B4" value="8221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.8" spread="8.5"/>
                    <measurement group_id="B2" value="76.7" spread="8.2"/>
                    <measurement group_id="B3" value="76.4" spread="8.7"/>
                    <measurement group_id="B4" value="76.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <population>The analysis population included all participants with a baseline weight measurement.</population>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2750"/>
                    <count group_id="B2" value="2746"/>
                    <count group_id="B3" value="2747"/>
                    <count group_id="B4" value="8243"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.9" spread="18.4"/>
                    <measurement group_id="B2" value="91.6" spread="18.6"/>
                    <measurement group_id="B3" value="91.9" spread="18.3"/>
                    <measurement group_id="B4" value="91.8" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C (A1C)</title>
          <population>The analysis population included all participants with a baseline A1C measurement.</population>
          <units>A1C Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2737"/>
                    <count group_id="B2" value="2737"/>
                    <count group_id="B3" value="2732"/>
                    <count group_id="B4" value="8206"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="1.0"/>
                    <measurement group_id="B2" value="8.2" spread="1.0"/>
                    <measurement group_id="B3" value="8.2" spread="0.9"/>
                    <measurement group_id="B4" value="8.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <population>The analysis population included all participants with a baseline eGFR measurement.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2751"/>
                    <count group_id="B2" value="2747"/>
                    <count group_id="B3" value="2747"/>
                    <count group_id="B4" value="8245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.0" spread="20.8"/>
                    <measurement group_id="B2" value="76.2" spread="20.9"/>
                    <measurement group_id="B3" value="75.7" spread="20.8"/>
                    <measurement group_id="B4" value="76.0" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study)</title>
        <description>Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke. The on-treatment approach included confirmed events that occurred between the date of first dose of study medication and the on-treatment censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or 365 days after the last dose).</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all participants who were randomized into the study and who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study)</title>
          <description>Time to the first occurrence of any of the following adjudicated components of the primary composite endpoint (3-point major adverse cardiovascular events (MACE)): cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke. The on-treatment approach included confirmed events that occurred between the date of first dose of study medication and the on-treatment censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or 365 days after the last dose).</description>
          <population>The analysis population included all participants who were randomized into the study and who received at least 1 dose of study medication.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
                <count group_id="O4" value="5493"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64"/>
                    <measurement group_id="O2" value="4.16"/>
                    <measurement group_id="O3" value="4.01"/>
                    <measurement group_id="O4" value="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>1-sided p-value and the non-inferiority margin is a hazard ratio of 1.3.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</p_value_desc>
            <method>Cox Proportional Hazards Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.848</ci_lower_limit>
            <ci_upper_limit>1.114</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>1-sided p-value and the non-inferiority margin is a hazard ratio of 1.3.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.887</ci_lower_limit>
            <ci_upper_limit>1.211</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>1-sided p-value and the non-inferiority margin is a hazard ratio of 1.3.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95.6</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.773</ci_lower_limit>
            <ci_upper_limit>1.065</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.</description>
        <time_frame>Baseline</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, and had a measurement of the analysis endpoint at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Ins+/-Met Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, and had a measurement of the analysis endpoint at Baseline.</population>
          <units>A1C Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.45" spread="0.944"/>
                    <measurement group_id="O2" value="8.38" spread="0.985"/>
                    <measurement group_id="O3" value="8.39" spread="0.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least 1 dose of study medication, and had at least 1 measurement of the analysis endpoint for the specified timepoint(s) from Baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Ins+/-Met Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least 1 dose of study medication, and had at least 1 measurement of the analysis endpoint for the specified timepoint(s) from Baseline to Week 18.</population>
          <units>A1C Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" lower_limit="-0.86" upper_limit="-0.67"/>
                    <measurement group_id="O2" value="-0.84" lower_limit="-0.93" upper_limit="-0.74"/>
                    <measurement group_id="O3" value="-0.19" lower_limit="-0.29" upper_limit="-0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, stratum, and the interaction of time by treatment. The stratum was (insulin alone or insulin+metformin) and &quot;Time&quot; was a categorical variable.</p_value_desc>
            <method>cLDA Model</method>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, stratum, and the interaction of time by treatment. The stratum was (insulin alone or insulin+metformin) and &quot;Time&quot; was a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.</description>
        <time_frame>Baseline</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Sulfonyl Monotherapy Glycemic Sub-study, and had a measurement of the analysis endpoint at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects the Week 0 A1C.</description>
          <population>The analysis population included all participants who were randomized, participated in the Sulfonyl Monotherapy Glycemic Sub-study, and had a measurement of the analysis endpoint at Baseline.</population>
          <units>A1C Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27" spread="0.999"/>
                    <measurement group_id="O2" value="8.39" spread="1.019"/>
                    <measurement group_id="O3" value="8.21" spread="1.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Sulfonyl Monotherapy Glycemic Sub-study, received at least 1 dose of study medication, and had at least 1 measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Sulfonyl Monotherapy Glycemic Sub-study, received at least 1 dose of study medication, and had at least 1 measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
          <units>A1C Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" lower_limit="-1.17" upper_limit="-0.65"/>
                    <measurement group_id="O2" value="-0.78" lower_limit="-1.06" upper_limit="-0.51"/>
                    <measurement group_id="O3" value="-0.56" lower_limit="-0.84" upper_limit="-0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.247</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, and the interaction of time by treatment.</p_value_desc>
            <method>cLDA Model</method>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.063</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, and the interaction of time by treatment.</p_value_desc>
            <method>cLDA model</method>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects Week 0 A1C.</description>
        <time_frame>Baseline</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, and had an assessment for the analysis endpoint at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This baseline reflects Week 0 A1C.</description>
          <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, and had an assessment for the analysis endpoint at Baseline.</population>
          <units>A1C Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.39" spread="0.960"/>
                    <measurement group_id="O2" value="8.30" spread="0.963"/>
                    <measurement group_id="O3" value="8.27" spread="0.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of blinded study medication, and had at least one assessment for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of blinded study medication, and had at least one assessment for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>A1C Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" lower_limit="-1.06" upper_limit="-0.71"/>
                    <measurement group_id="O2" value="-0.98" lower_limit="-1.14" upper_limit="-0.82"/>
                    <measurement group_id="O3" value="-0.23" lower_limit="-0.39" upper_limit="-0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, and the interaction of time by treatment.</p_value_desc>
            <method>cLDA Model</method>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR, and the interaction of time by treatment.</p_value_desc>
            <method>cLDA model</method>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of Cardiovascular (CV) Death or Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)</title>
        <description>Time to the occurrence of any of the following adjudicated components of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)) or hospitalization for heart failure. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Cardiovascular (CV) Death or Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)</title>
          <description>Time to the occurrence of any of the following adjudicated components of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)) or hospitalization for heart failure. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).</description>
          <population>The analysis population included all randomized participants.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2752"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2747"/>
                <count group_id="O4" value="5499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36"/>
                    <measurement group_id="O2" value="2.33"/>
                    <measurement group_id="O3" value="2.66"/>
                    <measurement group_id="O4" value="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.750</ci_lower_limit>
            <ci_upper_limit>1.034</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.150</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.725</ci_lower_limit>
            <ci_upper_limit>1.057</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.188</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.735</ci_lower_limit>
            <ci_upper_limit>1.068</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of Cardiovascular Death (On-study Approach) (Overall Cardiovascular Study)</title>
        <description>Time to the occurrence of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to CV death or time to censoring (the earliest of participants' end of study date or date last known to be alive).</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Cardiovascular Death (On-study Approach) (Overall Cardiovascular Study)</title>
          <description>Time to the occurrence of cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to CV death or time to censoring (the earliest of participants' end of study date or date last known to be alive).</description>
          <population>The analysis population included all randomized participants.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2752"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2747"/>
                <count group_id="O4" value="5499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77"/>
                    <measurement group_id="O2" value="1.74"/>
                    <measurement group_id="O3" value="1.90"/>
                    <measurement group_id="O4" value="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.385</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.767</ci_lower_limit>
            <ci_upper_limit>1.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.417</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.739</ci_lower_limit>
            <ci_upper_limit>1.139</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.494</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.750</ci_lower_limit>
            <ci_upper_limit>1.154</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of the Renal Composite: the Composite of Renal Death, Renal Dialysis/Transplant, or Doubling of Serum Creatinine From Baseline (On-Study Approach) (Overall Cardiovascular Study)</title>
        <description>Renal composite endpoint was defined as a composite of renal death, renal dialysis/transplant, or doubling of serum creatinine from baseline. The on-study approach included events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of the Renal Composite: the Composite of Renal Death, Renal Dialysis/Transplant, or Doubling of Serum Creatinine From Baseline (On-Study Approach) (Overall Cardiovascular Study)</title>
          <description>Renal composite endpoint was defined as a composite of renal death, renal dialysis/transplant, or doubling of serum creatinine from baseline. The on-study approach included events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
          <population>The analysis population included all randomized participants.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2752"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2747"/>
                <count group_id="O4" value="5499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87"/>
                    <measurement group_id="O2" value="0.98"/>
                    <measurement group_id="O3" value="1.15"/>
                    <measurement group_id="O4" value="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.081</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.630</ci_lower_limit>
            <ci_upper_limit>1.036</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.258</p_value>
            <method>Cox Proportional Hazard Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.&#xD;
Renal</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.638</ci_lower_limit>
            <ci_upper_limit>1.137</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.568</ci_lower_limit>
            <ci_upper_limit>1.028</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of MACE Plus (Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke or Hospitalization for Unstable Angina) (On-Study Approach) (Overall Cardiovascular Study)</title>
        <description>Time to the first occurrence of any of the following adjudicated components 4-point MACE: cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina pectoris. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of MACE Plus (Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke or Hospitalization for Unstable Angina) (On-Study Approach) (Overall Cardiovascular Study)</title>
          <description>Time to the first occurrence of any of the following adjudicated components 4-point MACE: cardiovascular death (including fatal stroke and fatal myocardial infarction), non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina pectoris. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
          <population>The analysis population included all randomized participants.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2752"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2747"/>
                <count group_id="O4" value="5499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42"/>
                    <measurement group_id="O2" value="4.67"/>
                    <measurement group_id="O3" value="4.92"/>
                    <measurement group_id="O4" value="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.183</p_value>
            <p_value_desc>Hazard ratio, CI, and 2-sided p-value comparing All Ertugliflozin versus Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.823</ci_lower_limit>
            <ci_upper_limit>1.038</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.450</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.831</ci_lower_limit>
            <ci_upper_limit>1.086</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.123</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.785</ci_lower_limit>
            <ci_upper_limit>1.029</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction (On-Study Approach) (Overall Cardiovascular Study)</title>
        <description>Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction (On-Study Approach) (Overall Cardiovascular Study)</title>
          <description>Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date).</description>
          <population>The analysis population included all randomized participants.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2752"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2747"/>
                <count group_id="O4" value="5499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55"/>
                    <measurement group_id="O2" value="2.00"/>
                    <measurement group_id="O3" value="1.70"/>
                    <measurement group_id="O4" value="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.676</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.861</ci_lower_limit>
            <ci_upper_limit>1.259</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.139</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.949</ci_lower_limit>
            <ci_upper_limit>1.451</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.416</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.727</ci_lower_limit>
            <ci_upper_limit>1.141</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of Fatal or Non-fatal Stroke (FNF Stroke) (On-Study Approach) (Overall Cardiovascular Study)</title>
        <description>Time to the first occurrence of fatal and no-fatal stroke. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of Fatal or Non-fatal Stroke (FNF Stroke) (On-Study Approach) (Overall Cardiovascular Study)</title>
          <description>Time to the first occurrence of fatal and no-fatal stroke. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
          <population>The analysis population included all randomized participants.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2752"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2747"/>
                <count group_id="O4" value="5499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92"/>
                    <measurement group_id="O2" value="1.04"/>
                    <measurement group_id="O3" value="0.93"/>
                    <measurement group_id="O4" value="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.663</p_value>
            <p_value_desc>Hazard ratio, CI, and 2-sided p-value comparing All Ertugliflozin versus Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.820</ci_lower_limit>
            <ci_upper_limit>1.365</ci_upper_limit>
            <estimate_desc>Hazard ratio, CI, and 2-sided p-value comparing All Ertugliflozin versus Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio, confidence interval, and two-sided p-value comparing Ertugliflozin vs Placebo, based on the stratified Cox proportional hazards model that includes treatment as an explanatory factor and cohort category as a stratification factor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.415</p_value>
            <p_value_desc>A two-sided p-value compared Ertugliflozin vs Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.845</ci_lower_limit>
            <ci_upper_limit>1.505</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio, confidence interval, and two-sided p-value comparing Ertugliflozin vs Placebo, based on the stratified Cox proportional hazards model that includes treatment as an explanatory factor and cohort category as a stratification factor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.953</p_value>
            <p_value_desc>A two-sided p-value compared Ertugliflozin vs Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.736</ci_lower_limit>
            <ci_upper_limit>1.334</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Occurrence of Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)</title>
        <description>Time to the first occurrence of heart failure requiring hospitalization (adjudicated). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Occurrence of Hospitalization for Heart Failure (HHF) (On-Study Approach) (Overall Cardiovascular Study)</title>
          <description>Time to the first occurrence of heart failure requiring hospitalization (adjudicated). The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to first event or time to censoring (the earliest of participants' end of study date, death date, or last contact date). The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
          <population>The analysis population included all randomized participants.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2752"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2747"/>
                <count group_id="O4" value="5499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75"/>
                    <measurement group_id="O2" value="0.72"/>
                    <measurement group_id="O3" value="1.05"/>
                    <measurement group_id="O4" value="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>Hazard ratio, CI, and 2-sided p-value comparing All Ertugliflozin versus Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.539</ci_lower_limit>
            <ci_upper_limit>0.902</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.502</ci_lower_limit>
            <ci_upper_limit>0.932</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.524</ci_lower_limit>
            <ci_upper_limit>0.964</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of Death From Any Cause (On-Study Approach) (Overall Cardiovascular Study)</title>
        <description>Time to the occurrence of death from any cause. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or date last known to be alive. The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Death From Any Cause (On-Study Approach) (Overall Cardiovascular Study)</title>
          <description>Time to the occurrence of death from any cause. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date. Person-years was calculated as the sum of participants' time to event or time to censoring (the earliest of participants' end of study date, death date, last contact date, or date last known to be alive. The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
          <population>The analysis population included all randomized participants.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2752"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2747"/>
                <count group_id="O4" value="5499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42"/>
                    <measurement group_id="O2" value="2.46"/>
                    <measurement group_id="O3" value="2.62"/>
                    <measurement group_id="O4" value="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Hazard ratio, CI, and 2-sided p-value comparing Ertugliflozin vs Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor. The on-study approach included confirmed events that occurred between the randomization date and the on-study censor date.</non_inferiority_desc>
            <p_value>0.340</p_value>
            <p_value_desc>Hazard ratio, CI, and 2-sided p-value comparing Ertugliflozin vs Placebo, based on the stratified Cox proportional hazards model that included treatment as an explanatory factor and cohort category as a stratification factor.</p_value_desc>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.797</ci_lower_limit>
            <ci_upper_limit>1.081</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.463</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.784</ci_lower_limit>
            <ci_upper_limit>1.117</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.363</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Model included treatment as an explanatory factor and cohort category as a stratification factor.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.771</ci_lower_limit>
            <ci_upper_limit>1.100</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Andersen-Gill Model for Total MACE (On-Study Approach) (Overall Cardiovascular Study)</title>
        <description>All events (first and recurrent) of the composite of MACE (3-point major adverse cardiovascular events: cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke) were assessed using Andersen-Gill model. The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Andersen-Gill Model for Total MACE (On-Study Approach) (Overall Cardiovascular Study)</title>
          <description>All events (first and recurrent) of the composite of MACE (3-point major adverse cardiovascular events: cardiovascular (CV) death (including fatal stroke and fatal myocardial infarction (MI)), non-fatal MI, and non-fatal stroke) were assessed using Andersen-Gill model. The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
          <population>The analysis population included all randomized participants.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2752"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2747"/>
                <count group_id="O4" value="5499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35"/>
                    <measurement group_id="O2" value="4.91"/>
                    <measurement group_id="O3" value="4.59"/>
                    <measurement group_id="O4" value="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Ertugliflozin vs Placebo, based on the Andersen-Gill model for the recurrent events at the end of study. The on-study approach includes confirmed events that occurred between the randomization date and the on-study censor date.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.898</ci_lower_limit>
            <ci_upper_limit>1.131</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.937</ci_lower_limit>
            <ci_upper_limit>1.219</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.828</ci_lower_limit>
            <ci_upper_limit>1.085</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Andersen-Gill Model for All Cardiovascular Death (CV Death) or Hospitalizations for Heart Failure (HFF) (On-Study Approach) (Overall Cardiovascular Study)</title>
        <description>All events (first and recurrent) of the composite of CV death and HHF were assessed using an Andersen-Gill model. Person-years were calculated as the sum of time from randomization to end of follow-up. The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Andersen-Gill Model for All Cardiovascular Death (CV Death) or Hospitalizations for Heart Failure (HFF) (On-Study Approach) (Overall Cardiovascular Study)</title>
          <description>All events (first and recurrent) of the composite of CV death and HHF were assessed using an Andersen-Gill model. Person-years were calculated as the sum of time from randomization to end of follow-up. The on-study approach included events that occurred between the randomization date and the on-study censor date.</description>
          <population>The analysis population included all randomized participants.</population>
          <units>Events per 100 Person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2752"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2747"/>
                <count group_id="O4" value="5499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92"/>
                    <measurement group_id="O2" value="2.71"/>
                    <measurement group_id="O3" value="3.42"/>
                    <measurement group_id="O4" value="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Ertugliflozin vs Placebo, based on the Andersen-Gill model for the recurrent events at the end of study. The on-study approach included confirmed events that occurred between randomization date and the on-study censor date.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.716</ci_lower_limit>
            <ci_upper_limit>0.945</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.673</ci_lower_limit>
            <ci_upper_limit>0.935</ci_upper_limit>
            <estimate_desc>Ertugliflozin vs Placebo, based on the Andersen-Gill model for the recurrent events at the end of study.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.725</ci_lower_limit>
            <ci_upper_limit>1.001</ci_upper_limit>
            <estimate_desc>Ertugliflozin vs Placebo, based on the Andersen-Gill model for the recurrent events at the end of study.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one assessment for the analysis endpoint for the specified timepoint(s) at or after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 18 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one assessment for the analysis endpoint for the specified timepoint(s) at or after baseline.</population>
          <units>A1C Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2745"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2742"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" lower_limit="-0.73" upper_limit="-0.67"/>
                    <measurement group_id="O2" value="-0.72" lower_limit="-0.75" upper_limit="-0.69"/>
                    <measurement group_id="O3" value="-0.22" lower_limit="-0.25" upper_limit="-0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA Model</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA model</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Week 52 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one assessment for the analysis endpoint for the specified timepoint(s) at or after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Week 52 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one assessment for the analysis endpoint for the specified timepoint(s) at or after baseline.</population>
          <units>A1C Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" lower_limit="-0.73" upper_limit="-0.65"/>
                    <measurement group_id="O2" value="-0.67" lower_limit="-0.71" upper_limit="-0.63"/>
                    <measurement group_id="O3" value="-0.19" lower_limit="-0.23" upper_limit="-0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model included fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <method_desc>Model included fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>-0.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Month 24 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 24 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one assessment for the specified timepoint(s) at or after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Month 24 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 24 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one assessment for the specified timepoint(s) at or after baseline.</population>
          <units>A1C Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" lower_limit="-0.52" upper_limit="-0.43"/>
                    <measurement group_id="O2" value="-0.46" lower_limit="-0.50" upper_limit="-0.41"/>
                    <measurement group_id="O3" value="-0.08" lower_limit="-0.14" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
            <estimate_desc>Ertugliflozin vs. Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>cLDA</method>
            <method_desc>Ertugliflozin vs. Placebo.</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Month 36 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 36 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both baseline and Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Month 36 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 36 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both baseline and Month 36.</population>
          <units>A1C Percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1590"/>
                <count group_id="O2" value="1574"/>
                <count group_id="O3" value="1501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" lower_limit="-0.47" upper_limit="-0.37"/>
                    <measurement group_id="O2" value="-0.38" lower_limit="-0.43" upper_limit="-0.33"/>
                    <measurement group_id="O3" value="-0.04" lower_limit="-0.10" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Month 48 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 48 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 48</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one assessment for specified timepoint(s) at or after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Month 48 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 48 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one assessment for specified timepoint(s) at or after baseline.</population>
          <units>A1C Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" lower_limit="-0.29" upper_limit="-0.15"/>
                    <measurement group_id="O2" value="-0.17" lower_limit="-0.24" upper_limit="-0.10"/>
                    <measurement group_id="O3" value="0.14" lower_limit="0.07" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>cLDA</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>cLDA model</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Month 60 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 60 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both baseline and Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Month 60 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 60 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both baseline and Month 60.</population>
          <units>A1C Percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
                <count group_id="O2" value="527"/>
                <count group_id="O3" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-0.35" upper_limit="-0.15"/>
                    <measurement group_id="O2" value="-0.28" lower_limit="-0.38" upper_limit="-0.18"/>
                    <measurement group_id="O3" value="-0.10" lower_limit="-0.20" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in A1C at Month 72 (Overall Cardiovascular Study)</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 72 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 72</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both baseline and Month 72.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in A1C at Month 72 (Overall Cardiovascular Study)</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Month 72 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both baseline and Month 72.</population>
          <units>A1C Percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" lower_limit="-0.89" upper_limit="0.20"/>
                    <measurement group_id="O2" value="-0.13" lower_limit="-0.99" upper_limit="0.74"/>
                    <measurement group_id="O3" value="0.24" lower_limit="-0.74" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Week 18</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Week 18.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2544"/>
                <count group_id="O2" value="2520"/>
                <count group_id="O3" value="2527"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="28.2"/>
                    <measurement group_id="O3" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 52 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Week 52</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 52 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Week 52.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2347"/>
                <count group_id="O3" value="2311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="29.0"/>
                    <measurement group_id="O3" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 24 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Month 24</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 24 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 24.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1570"/>
                <count group_id="O2" value="1541"/>
                <count group_id="O3" value="1496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="23.8"/>
                    <measurement group_id="O3" value="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 36 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Month 36</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 36 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 36.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1592"/>
                <count group_id="O2" value="1578"/>
                <count group_id="O3" value="1507"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 48 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Month 48</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 48 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 48.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="876"/>
                <count group_id="O2" value="860"/>
                <count group_id="O3" value="786"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 60 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Month 60</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Month 60 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 60.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
                <count group_id="O2" value="529"/>
                <count group_id="O3" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Week 18 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Week 18</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Week 18 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Week 18.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2544"/>
                <count group_id="O2" value="2520"/>
                <count group_id="O3" value="2727"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Week 52 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Week 52</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Week 52 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Week 52.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2347"/>
                <count group_id="O3" value="2311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="10.9"/>
                    <measurement group_id="O3" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 24 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Month 24</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 24 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 24.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1570"/>
                <count group_id="O2" value="1541"/>
                <count group_id="O3" value="1496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="8.6"/>
                    <measurement group_id="O3" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 36 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Month 36</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 36 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 36.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1592"/>
                <count group_id="O2" value="1578"/>
                <count group_id="O3" value="1507"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 48 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Month 48</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 48 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 48.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="876"/>
                <count group_id="O2" value="860"/>
                <count group_id="O3" value="786"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 60 (Overall Cardiovascular Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Month 60</time_frame>
        <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;6.5% (&lt;48 mmol/Mol) at Month 60 (Overall Cardiovascular Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all randomized and treated participants with an A1C measurement for the analysis endpoint for the specified timepoint(s) at Month 60.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
                <count group_id="O2" value="529"/>
                <count group_id="O3" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="9.5"/>
                    <measurement group_id="O3" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</title>
        <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding rescue&quot;, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</title>
          <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding rescue&quot;, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2745"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2744"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.18" lower_limit="-33.76" upper_limit="-30.61"/>
                    <measurement group_id="O2" value="-34.64" lower_limit="-36.21" upper_limit="-33.08"/>
                    <measurement group_id="O3" value="-17.08" lower_limit="-18.69" upper_limit="-15.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>CLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-17.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.49</ci_lower_limit>
            <ci_upper_limit>-15.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-15.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.03</ci_lower_limit>
            <ci_upper_limit>-13.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Overall Cardiovascular Study)</title>
        <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 52 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 (Overall Cardiovascular Study)</title>
          <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 52 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 52.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2352"/>
                <count group_id="O2" value="2328"/>
                <count group_id="O3" value="2295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.63" lower_limit="-30.52" upper_limit="-26.74"/>
                    <measurement group_id="O2" value="-28.97" lower_limit="-30.78" upper_limit="-27.15"/>
                    <measurement group_id="O3" value="-8.76" lower_limit="-10.75" upper_limit="-6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 24 (Overall Cardiovascular Study)</title>
        <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 24 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 24 (Overall Cardiovascular Study)</title>
          <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 24 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 24.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1562"/>
                <count group_id="O2" value="1536"/>
                <count group_id="O3" value="1487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.09" lower_limit="-24.39" upper_limit="-19.80"/>
                    <measurement group_id="O2" value="-24.31" lower_limit="-26.76" upper_limit="-21.86"/>
                    <measurement group_id="O3" value="-4.39" lower_limit="-6.99" upper_limit="-1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 36 (Overall Cardiovascular Study)</title>
        <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 36 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 36 (Overall Cardiovascular Study)</title>
          <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 36 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1579"/>
                <count group_id="O2" value="1567"/>
                <count group_id="O3" value="1491"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.39" lower_limit="-21.88" upper_limit="-16.89"/>
                    <measurement group_id="O2" value="-22.59" lower_limit="-24.96" upper_limit="-20.21"/>
                    <measurement group_id="O3" value="-3.63" lower_limit="-6.45" upper_limit="-0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 48 (Overall Cardiovascular Study)</title>
        <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 48 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 48</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 48 (Overall Cardiovascular Study)</title>
          <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 48 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 48.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="868"/>
                <count group_id="O2" value="861"/>
                <count group_id="O3" value="777"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.28" lower_limit="-18.66" upper_limit="-11.90"/>
                    <measurement group_id="O2" value="-16.16" lower_limit="-19.50" upper_limit="-12.83"/>
                    <measurement group_id="O3" value="3.59" lower_limit="-0.22" upper_limit="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 60 (Overall Cardiovascular Study)</title>
        <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 60 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 60 (Overall Cardiovascular Study)</title>
          <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 60 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="520"/>
                <count group_id="O2" value="524"/>
                <count group_id="O3" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.87" lower_limit="-18.34" upper_limit="-9.40"/>
                    <measurement group_id="O2" value="-11.15" lower_limit="-15.78" upper_limit="-6.52"/>
                    <measurement group_id="O3" value="-4.69" lower_limit="-9.72" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 72 (Overall Cardiovascular Study)</title>
        <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 72 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 72</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both baseline and Month 72.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Month 72 (Overall Cardiovascular Study)</title>
          <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Month 72 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both baseline and Month 72.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" lower_limit="-31.28" upper_limit="26.36"/>
                    <measurement group_id="O2" value="-84.83" lower_limit="-127.31" upper_limit="-42.35"/>
                    <measurement group_id="O3" value="14.56" lower_limit="-23.11" upper_limit="52.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First Occurrence of a Participant Receiving Glycemic Rescue Therapy Through Week 18 (Overall Cardiovascular Study)</title>
        <description>Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
        <time_frame>Up to 18 weeks</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and received glycemic rescue by Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Occurrence of a Participant Receiving Glycemic Rescue Therapy Through Week 18 (Overall Cardiovascular Study)</title>
          <description>Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and received glycemic rescue by Week 18.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" lower_limit="36" upper_limit="99"/>
                    <measurement group_id="O2" value="51.0" lower_limit="18" upper_limit="91"/>
                    <measurement group_id="O3" value="74.0" lower_limit="37" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>Log-Rank Test for the comparison to Placebo was based on all data (including for those participants who never had the event).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>Log-Rank Test for the comparison to Placebo was based on all data (including for those participants who never had the event).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Initiation of Insulin for Participants Not on Insulin at Baseline (Overall Cardiovascular Study)</title>
        <description>Participants who were not on insulin therapy at the start of study medication.</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and were not on insulin therapy at the start of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Initiation of Insulin for Participants Not on Insulin at Baseline (Overall Cardiovascular Study)</title>
          <description>Participants who were not on insulin therapy at the start of study medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and were not on insulin therapy at the start of study medication.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1442"/>
                <count group_id="O2" value="1499"/>
                <count group_id="O3" value="1400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="602" lower_limit="8" upper_limit="1850"/>
                    <measurement group_id="O2" value="650" lower_limit="16" upper_limit="1934"/>
                    <measurement group_id="O3" value="482" lower_limit="10" upper_limit="1838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>Log-Rank Test for the comparison to Placebo was based on all data (including for those participants who never had the event).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>Log-Rank Test for the comparison to Placebo was based on all data (including for those participants who never had the event).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Insulin Dose for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
        <description>Baseline reflects Week 0 insulin dose.</description>
        <time_frame>Baseline</time_frame>
        <population>The analysis population included all participants who were randomized and were treated with insulin at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Insulin Dose for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
          <description>Baseline reflects Week 0 insulin dose.</description>
          <population>The analysis population included all participants who were randomized and were treated with insulin at Baseline.</population>
          <units>Units/Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1248"/>
                <count group_id="O3" value="1345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.82" spread="48.11"/>
                    <measurement group_id="O2" value="62.15" spread="44.46"/>
                    <measurement group_id="O3" value="65.74" spread="46.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Dose at Week 18 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Dose at Week 18 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 18.</population>
          <units>Units/Day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1297"/>
                <count group_id="O2" value="1237"/>
                <count group_id="O3" value="1304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.29" upper_limit="1.82"/>
                    <measurement group_id="O2" value="0.81" lower_limit="-0.10" upper_limit="1.71"/>
                    <measurement group_id="O3" value="3.71" lower_limit="2.72" upper_limit="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Dose at Week 52 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 52 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Dose at Week 52 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 52 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 52.</population>
          <units>Units/Day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1103"/>
                <count group_id="O2" value="1067"/>
                <count group_id="O3" value="1130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" lower_limit="-0.15" upper_limit="1.82"/>
                    <measurement group_id="O2" value="-1.69" lower_limit="-2.83" upper_limit="-0.54"/>
                    <measurement group_id="O3" value="5.57" lower_limit="4.16" upper_limit="6.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Dose at Month 24 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 24 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Dose at Month 24 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 24 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 24.</population>
          <units>Units/Day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1004"/>
                <count group_id="O2" value="966"/>
                <count group_id="O3" value="998"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="-0.72" upper_limit="1.63"/>
                    <measurement group_id="O2" value="-1.58" lower_limit="-2.95" upper_limit="-0.21"/>
                    <measurement group_id="O3" value="6.16" lower_limit="4.47" upper_limit="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Dose at Month 36 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 36 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Dose at Month 36 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 36 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
          <units>Units/Day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="465"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" lower_limit="-0.77" upper_limit="4.05"/>
                    <measurement group_id="O2" value="-1.92" lower_limit="-4.31" upper_limit="0.46"/>
                    <measurement group_id="O3" value="7.99" lower_limit="4.65" upper_limit="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Dose at Month 48 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 48 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
        <time_frame>Baseline and Month 48</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Dose at Month 48 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 48 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 48.</population>
          <units>Units/Day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="384"/>
                <count group_id="O3" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" lower_limit="0.41" upper_limit="5.51"/>
                    <measurement group_id="O2" value="-1.87" lower_limit="-4.80" upper_limit="1.05"/>
                    <measurement group_id="O3" value="7.28" lower_limit="3.66" upper_limit="10.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Dose at Month 60 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 60 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Dose at Month 60 for Participants Who Were on Insulin at Baseline (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 60 insulin dose minus the Week 0 insulin dose. A negative number indicates a reduction in the insulin dose.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, were treated with insulin at Baseline, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
          <units>Units/Day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" lower_limit="-9.65" upper_limit="4.72"/>
                    <measurement group_id="O2" value="-1.77" lower_limit="-11.95" upper_limit="8.42"/>
                    <measurement group_id="O3" value="9.42" lower_limit="1.46" upper_limit="17.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding rescue&quot;, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding rescue&quot;, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2746"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" lower_limit="-3.00" upper_limit="-2.02"/>
                    <measurement group_id="O2" value="-2.75" lower_limit="-3.24" upper_limit="-2.26"/>
                    <measurement group_id="O3" value="0.03" lower_limit="-0.48" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.45</ci_lower_limit>
            <ci_upper_limit>-2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.21</ci_lower_limit>
            <ci_upper_limit>-1.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 52 sitting SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 52 sitting SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" lower_limit="-2.35" upper_limit="-1.32"/>
                    <measurement group_id="O2" value="-2.41" lower_limit="-2.92" upper_limit="-1.89"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.23" upper_limit="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Mean</param_type>
            <param_value>-3.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.85</ci_lower_limit>
            <ci_upper_limit>-2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.28</ci_lower_limit>
            <ci_upper_limit>-1.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 24 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 24 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 24 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 24 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" lower_limit="-2.42" upper_limit="-1.19"/>
                    <measurement group_id="O2" value="-1.82" lower_limit="-2.44" upper_limit="-1.19"/>
                    <measurement group_id="O3" value="0.90" lower_limit="0.27" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.57</ci_lower_limit>
            <ci_upper_limit>-1.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.56</ci_lower_limit>
            <ci_upper_limit>-1.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 36 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 36 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 36 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 36 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1593"/>
                <count group_id="O2" value="1580"/>
                <count group_id="O3" value="1505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="14.56"/>
                    <measurement group_id="O2" value="-1.21" spread="15.05"/>
                    <measurement group_id="O3" value="0.84" spread="14.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 48 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 48 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 48</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 48 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 48 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.07" lower_limit="-2.84" upper_limit="-1.31"/>
                    <measurement group_id="O2" value="-2.26" lower_limit="-3.03" upper_limit="-1.49"/>
                    <measurement group_id="O3" value="0.53" lower_limit="-0.27" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.68</ci_lower_limit>
            <ci_upper_limit>-1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.87</ci_lower_limit>
            <ci_upper_limit>-1.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 60 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 60 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 60 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 60 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="529"/>
                <count group_id="O3" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="15.39"/>
                    <measurement group_id="O2" value="-1.87" spread="15.01"/>
                    <measurement group_id="O3" value="0.62" spread="15.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 72 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 72 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 72</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 72.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Month 72 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 72 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 72.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="-7.63" upper_limit="10.20"/>
                    <measurement group_id="O2" value="-3.46" lower_limit="-10.91" upper_limit="3.99"/>
                    <measurement group_id="O3" value="2.72" lower_limit="-5.95" upper_limit="11.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding rescue&quot;, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding rescue&quot;, excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint at or after Baseline.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2746"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" lower_limit="-1.29" upper_limit="-0.70"/>
                    <measurement group_id="O2" value="-1.08" lower_limit="-1.38" upper_limit="-0.79"/>
                    <measurement group_id="O3" value="-0.12" lower_limit="-0.42" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.37</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Means Squares</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>-0.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 52 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 52 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 52 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 52 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" lower_limit="-1.28" upper_limit="-0.67"/>
                    <measurement group_id="O2" value="-0.95" lower_limit="-1.26" upper_limit="-0.65"/>
                    <measurement group_id="O3" value="-0.15" lower_limit="-0.45" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.24</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 24 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 24 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 24 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 24 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after baseline.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" lower_limit="-1.31" upper_limit="-0.57"/>
                    <measurement group_id="O2" value="-0.90" lower_limit="-1.27" upper_limit="-0.53"/>
                    <measurement group_id="O3" value="-0.23" lower_limit="-0.60" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 36 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 36 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 36 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 36 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1593"/>
                <count group_id="O2" value="1580"/>
                <count group_id="O3" value="1505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="8.94"/>
                    <measurement group_id="O2" value="-0.92" spread="8.89"/>
                    <measurement group_id="O3" value="-0.22" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 48 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 48 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 48</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 48 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 48 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="881"/>
                <count group_id="O2" value="868"/>
                <count group_id="O3" value="789"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" lower_limit="-1.93" upper_limit="-0.97"/>
                    <measurement group_id="O2" value="-1.42" lower_limit="-1.90" upper_limit="-0.94"/>
                    <measurement group_id="O3" value="-0.64" lower_limit="-1.14" upper_limit="-0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.024</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</p_value_desc>
            <method>Constrained longitudinal data analysis</method>
            <param_type>Difference in the least squares means</param_type>
            <param_value>-0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.48</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 60 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 60 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 60 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 60 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="529"/>
                <count group_id="O3" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" spread="8.66"/>
                    <measurement group_id="O2" value="-1.43" spread="9.36"/>
                    <measurement group_id="O3" value="-1.26" spread="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 72 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 72 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 72</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Month 72 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 72 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and time point.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" lower_limit="-7.65" upper_limit="3.29"/>
                    <measurement group_id="O2" value="1.86" lower_limit="-2.73" upper_limit="6.45"/>
                    <measurement group_id="O3" value="7.29" lower_limit="1.63" upper_limit="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and have at least and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and have at least and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2746"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" lower_limit="-2.14" upper_limit="-1.92"/>
                    <measurement group_id="O2" value="-2.32" lower_limit="-2.43" upper_limit="-2.22"/>
                    <measurement group_id="O3" value="-0.40" lower_limit="-0.51" upper_limit="-0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-1.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.07</ci_lower_limit>
            <ci_upper_limit>-1.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.78</ci_lower_limit>
            <ci_upper_limit>-1.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 52 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 52 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2746"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" lower_limit="-2.61" upper_limit="-2.31"/>
                    <measurement group_id="O2" value="-2.84" lower_limit="-2.99" upper_limit="-2.69"/>
                    <measurement group_id="O3" value="-0.39" lower_limit="-0.54" upper_limit="-0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.67</ci_lower_limit>
            <ci_upper_limit>-2.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.28</ci_lower_limit>
            <ci_upper_limit>-1.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Month 24 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 24 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Month 24 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 24 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after baseline.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2746"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" lower_limit="-2.95" upper_limit="-2.56"/>
                    <measurement group_id="O2" value="-3.17" lower_limit="-3.39" upper_limit="-2.95"/>
                    <measurement group_id="O3" value="-0.65" lower_limit="-0.85" upper_limit="-0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.83</ci_lower_limit>
            <ci_upper_limit>-2.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>-1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Month 36 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 36 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and have at least one measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Month 36 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 36 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and have at least one measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1595"/>
                <count group_id="O2" value="1578"/>
                <count group_id="O3" value="1506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.03" lower_limit="-3.24" upper_limit="-2.82"/>
                    <measurement group_id="O2" value="-3.41" lower_limit="-3.63" upper_limit="-3.20"/>
                    <measurement group_id="O3" value="-0.98" lower_limit="-1.20" upper_limit="-0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Month 48 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 48 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 48</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Month 48 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 48 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after baseline).</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2746"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.39" lower_limit="-3.69" upper_limit="-3.10"/>
                    <measurement group_id="O2" value="-3.83" lower_limit="-4.14" upper_limit="-3.51"/>
                    <measurement group_id="O3" value="-1.29" lower_limit="-1.59" upper_limit="-1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.97</ci_lower_limit>
            <ci_upper_limit>-2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.52</ci_lower_limit>
            <ci_upper_limit>-1.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Month 60 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 60 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Month 60 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 60 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="526"/>
                <count group_id="O2" value="530"/>
                <count group_id="O3" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.66" lower_limit="-4.11" upper_limit="-3.20"/>
                    <measurement group_id="O2" value="-4.58" lower_limit="-5.06" upper_limit="-4.11"/>
                    <measurement group_id="O3" value="-1.21" lower_limit="-1.63" upper_limit="-0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Month 72 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 72 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 72</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 72.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Month 72 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 72 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 72.</population>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.18" lower_limit="-7.83" upper_limit="-0.53"/>
                    <measurement group_id="O2" value="-7.37" lower_limit="-12.67" upper_limit="-2.07"/>
                    <measurement group_id="O3" value="-0.98" lower_limit="-4.13" upper_limit="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 18 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 18 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 18 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 18 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2671"/>
                <count group_id="O2" value="2667"/>
                <count group_id="O3" value="2661"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" lower_limit="-1.66" upper_limit="-0.77"/>
                    <measurement group_id="O2" value="-1.81" lower_limit="-2.26" upper_limit="-1.36"/>
                    <measurement group_id="O3" value="-0.03" lower_limit="-0.48" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in the Lease Squares Means</param_type>
            <param_value>-1.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.41</ci_lower_limit>
            <ci_upper_limit>-1.15</ci_upper_limit>
            <other_analysis_desc>Based on cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.82</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
            <other_analysis_desc>Based on cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 52 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had for the analysis endpoint for the specified timepoint(s) a Baseline measurement and at least one measurement at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 52 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had for the analysis endpoint for the specified timepoint(s) a Baseline measurement and at least one measurement at or after Baseline.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2671"/>
                <count group_id="O2" value="2669"/>
                <count group_id="O3" value="2664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" lower_limit="-1.01" upper_limit="-0.02"/>
                    <measurement group_id="O2" value="-1.18" lower_limit="-1.67" upper_limit="-0.68"/>
                    <measurement group_id="O3" value="-0.30" lower_limit="-0.80" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in the Lease Squares Means</param_type>
            <param_value>-0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.58</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
            <other_analysis_desc>Based on cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
            <other_analysis_desc>Based on cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 24 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 24 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 24 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 24 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline at or after Baseline.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1576"/>
                <count group_id="O2" value="1547"/>
                <count group_id="O3" value="1509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" lower_limit="-2.07" upper_limit="-0.90"/>
                    <measurement group_id="O2" value="-2.35" lower_limit="-2.94" upper_limit="-1.76"/>
                    <measurement group_id="O3" value="-2.60" lower_limit="-3.20" upper_limit="-2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in the least squares means</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in the least squares means</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
            <estimate_desc>Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 36 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 36 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 36 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 36 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1591"/>
                <count group_id="O2" value="1577"/>
                <count group_id="O3" value="1504"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="14.0"/>
                    <measurement group_id="O2" value="-2.3" spread="13.4"/>
                    <measurement group_id="O3" value="-3.8" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 48 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 48 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.</description>
        <time_frame>Baseline and Month 48</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had for the analysis endpoint for the specified timepoint(s) a Baseline measurement and at least one assessment at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 48 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 48 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in eGFR level.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had for the analysis endpoint for the specified timepoint(s) a Baseline measurement and at least one assessment at or after Baseline.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2671"/>
                <count group_id="O2" value="2669"/>
                <count group_id="O3" value="2665"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" lower_limit="-3.56" upper_limit="-1.94"/>
                    <measurement group_id="O2" value="-2.93" lower_limit="-3.73" upper_limit="-2.13"/>
                    <measurement group_id="O3" value="-4.41" lower_limit="-5.27" upper_limit="-3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in the Lease Squares Means</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
            <other_analysis_desc>Based on cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>2.84</ci_upper_limit>
            <other_analysis_desc>Based on cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 60 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 60 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 60 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 60 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="520"/>
                <count group_id="O2" value="529"/>
                <count group_id="O3" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="15.4"/>
                    <measurement group_id="O2" value="-2.9" spread="14.1"/>
                    <measurement group_id="O3" value="-6.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 72 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 72 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
        <time_frame>Baseline and Month 72</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Month 72 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 72 eGFR minus the Week 0 eGFR. A negative number indicates a reduction in the eGFR level.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and time point.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="12.9"/>
                    <measurement group_id="O2" value="0.2" spread="12.2"/>
                    <measurement group_id="O3" value="-1.8" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Serum Creatinine (Overall Cardiovascular Study)</title>
        <description>Baseline reflects Week 0 serum creatinine.</description>
        <time_frame>Baseline</time_frame>
        <population>The analysis population included all participants who were randomized and had a measurement for the analysis endpoint for the specified timepoint at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O4">
            <title>All Ertugliflozin (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg or 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Serum Creatinine (Overall Cardiovascular Study)</title>
          <description>Baseline reflects Week 0 serum creatinine.</description>
          <population>The analysis population included all participants who were randomized and had a measurement for the analysis endpoint for the specified timepoint at Baseline.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2739"/>
                <count group_id="O2" value="2740"/>
                <count group_id="O3" value="2736"/>
                <count group_id="O4" value="5479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.992" spread="0.278"/>
                    <measurement group_id="O2" value="0.985" spread="0.277"/>
                    <measurement group_id="O3" value="0.991" spread="0.281"/>
                    <measurement group_id="O4" value="0.998" spread="0.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Week 18 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 18 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Week 18 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 18 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 18.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2540"/>
                <count group_id="O2" value="2520"/>
                <count group_id="O3" value="2524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.154"/>
                    <measurement group_id="O2" value="0.032" spread="0.148"/>
                    <measurement group_id="O3" value="-0.002" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Week 52 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Week 52 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Week 52 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Week 52 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 52.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2360"/>
                <count group_id="O2" value="2344"/>
                <count group_id="O3" value="2314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.013" spread="0.166"/>
                    <measurement group_id="O2" value="0.023" spread="0.163"/>
                    <measurement group_id="O3" value="0.004" spread="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Month 24 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 24 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Month 24 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 24 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 24.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1574"/>
                <count group_id="O2" value="1548"/>
                <count group_id="O3" value="1506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024" spread="0.176"/>
                    <measurement group_id="O2" value="0.035" spread="0.187"/>
                    <measurement group_id="O3" value="0.034" spread="0.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Month 36 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 36 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Month 36 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 36 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1589"/>
                <count group_id="O2" value="1575"/>
                <count group_id="O3" value="1499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" spread="0.194"/>
                    <measurement group_id="O2" value="0.035" spread="0.188"/>
                    <measurement group_id="O3" value="0.049" spread="0.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Month 48 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 48 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 48</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Month 48 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 48 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 48.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="875"/>
                <count group_id="O2" value="865"/>
                <count group_id="O3" value="787"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032" spread="0.206"/>
                    <measurement group_id="O2" value="0.036" spread="0.196"/>
                    <measurement group_id="O3" value="0.059" spread="0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Month 60 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 60 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Month 60 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 60 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="528"/>
                <count group_id="O3" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="0.202"/>
                    <measurement group_id="O2" value="0.042" spread="0.216"/>
                    <measurement group_id="O3" value="0.098" spread="0.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Creatinine at Month 72 (Overall Cardiovascular Study)</title>
        <description>This change from baseline reflects the Month 72 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 72</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 72.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Creatinine at Month 72 (Overall Cardiovascular Study)</title>
          <description>This change from baseline reflects the Month 72 serum creatinine minus the Week 0 serum creatinine. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 72.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.034" spread="0.176"/>
                    <measurement group_id="O2" value="0.001" spread="0.120"/>
                    <measurement group_id="O3" value="-0.013" spread="0.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Urinary Albumin/Creatinine Ratio (Overall Cardiovascular Study)</title>
        <description>Baseline reflects Week 0 albumin/creatinine ratio.</description>
        <time_frame>Baseline</time_frame>
        <population>The analysis population included all participants who were randomized and had a measurement for the analysis endpoint for the specified timepoint at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Urinary Albumin/Creatinine Ratio (Overall Cardiovascular Study)</title>
          <description>Baseline reflects Week 0 albumin/creatinine ratio.</description>
          <population>The analysis population included all participants who were randomized and had a measurement for the analysis endpoint for the specified timepoint at baseline.</population>
          <units>mg/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2686"/>
                <count group_id="O2" value="2660"/>
                <count group_id="O3" value="2684"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.00" lower_limit="6.00" upper_limit="68.00"/>
                    <measurement group_id="O2" value="19.00" lower_limit="6.00" upper_limit="69.00"/>
                    <measurement group_id="O3" value="19.00" lower_limit="6.00" upper_limit="66.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 18 (Overall Cardiovascular Study)</title>
        <description>This percent change relative to baseline reflects the Week 18 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 18 (Overall Cardiovascular Study)</title>
          <description>This percent change relative to baseline reflects the Week 18 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 18.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2472"/>
                <count group_id="O2" value="2450"/>
                <count group_id="O3" value="2478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.40" lower_limit="-53.52" upper_limit="50.00"/>
                    <measurement group_id="O2" value="-14.71" lower_limit="-55.53" upper_limit="50.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-44.44" upper_limit="66.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 52 (Overall Cardiovascular Study)</title>
        <description>This percent change relative to baseline reflects the Week 52 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Week 52 (Overall Cardiovascular Study)</title>
          <description>This percent change relative to baseline reflects the Week 52 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in the albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Week 52.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2306"/>
                <count group_id="O2" value="2277"/>
                <count group_id="O3" value="2257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.53" lower_limit="-50.00" upper_limit="66.67"/>
                    <measurement group_id="O2" value="-6.82" lower_limit="-50.00" upper_limit="66.67"/>
                    <measurement group_id="O3" value="5.41" lower_limit="-40.00" upper_limit="96.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 24 (Overall Cardiovascular Study)</title>
        <description>This percent change relative to baseline reflects the Month 24 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 24 (Overall Cardiovascular Study)</title>
          <description>This percent change relative to baseline reflects the Month 24 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 24.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2125"/>
                <count group_id="O2" value="2084"/>
                <count group_id="O3" value="2025"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" lower_limit="-48.96" upper_limit="100.00"/>
                    <measurement group_id="O2" value="1.06" lower_limit="-47.78" upper_limit="95.26"/>
                    <measurement group_id="O3" value="17.14" lower_limit="-38.00" upper_limit="140.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 36 (Overall Cardiovascular Study)</title>
        <description>This percent change relative to baseline reflects the Month 36 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 36 (Overall Cardiovascular Study)</title>
          <description>This percent change relative to baseline reflects the Month 36 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in urinary albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 36.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1933"/>
                <count group_id="O2" value="1915"/>
                <count group_id="O3" value="1841"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33" lower_limit="-49.34" upper_limit="120.37"/>
                    <measurement group_id="O2" value="3.33" lower_limit="-49.44" upper_limit="100.00"/>
                    <measurement group_id="O3" value="27.03" lower_limit="-38.46" upper_limit="177.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 48 (Overall Cardiovascular Study)</title>
        <description>This percent change relative to baseline reflects the Month 48 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 48</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 48 (Overall Cardiovascular Study)</title>
          <description>This percent change relative to baseline reflects the Month 48 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 48.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
                <count group_id="O2" value="835"/>
                <count group_id="O3" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.33" lower_limit="-36.84" upper_limit="200.00"/>
                    <measurement group_id="O2" value="21.25" lower_limit="-42.86" upper_limit="150.00"/>
                    <measurement group_id="O3" value="50.00" lower_limit="-33.33" upper_limit="227.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 60 (Overall Cardiovascular Study)</title>
        <description>This percent change relative to baseline reflects the Month 60 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
        <time_frame>Baseline and Month 60</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Urinary Albumin/Creatinine Ratio at Month 60 (Overall Cardiovascular Study)</title>
          <description>This percent change relative to baseline reflects the Month 60 albumin/creatinine ratio minus the Week 0 albumin/creatinine ratio. This difference was divided by the baseline to obtain the percent change. A negative number indicates a reduction in albumin/creatinine ratio. Participants who met glycemic rescue criteria received glycemic rescue medication.</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, and had a measurement for the analysis endpoint for the specified timepoint(s) at both Baseline and Month 60.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="780"/>
                <count group_id="O2" value="771"/>
                <count group_id="O3" value="692"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.99" lower_limit="-40.00" upper_limit="200.00"/>
                    <measurement group_id="O2" value="20.00" lower_limit="-45.83" upper_limit="150.00"/>
                    <measurement group_id="O3" value="48.53" lower_limit="-28.57" upper_limit="222.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Albuminuria Progression or Regression at Week 18 (Overall Cardiovascular Study)</title>
        <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal-albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
        <time_frame>Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Albuminuria Progression or Regression at Week 18 (Overall Cardiovascular Study)</title>
          <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal-albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Week 18.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2472"/>
                <count group_id="O2" value="2450"/>
                <count group_id="O3" value="2478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Participants with albuminuria progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Participants with albuminuria regression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                    <measurement group_id="O2" value="14.7"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Albuminuria Progression or Regression at Week 52 (Overall Cardiovascular Study)</title>
        <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
        <time_frame>Week 52</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Albuminuria Progression or Regression at Week 52 (Overall Cardiovascular Study)</title>
          <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Week 52.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2306"/>
                <count group_id="O2" value="2277"/>
                <count group_id="O3" value="2257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Participants with albuminuria progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="10.2"/>
                    <measurement group_id="O3" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Participants with albuminuria regression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="14.8"/>
                    <measurement group_id="O3" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Albuminuria Progression or Regression at Month 24 (Overall Cardiovascular Study)</title>
        <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
        <time_frame>Month 24</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Albuminuria Progression or Regression at Month 24 (Overall Cardiovascular Study)</title>
          <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Month 24.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2125"/>
                <count group_id="O2" value="2084"/>
                <count group_id="O3" value="2025"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Participants with albuminuria progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="11.0"/>
                    <measurement group_id="O3" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Participants with albuminuria regression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Albuminuria Progression or Regression at Month 36 (Overall Cardiovascular Study)</title>
        <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
        <time_frame>Month 36</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Albuminuria Progression or Regression at Month 36 (Overall Cardiovascular Study)</title>
          <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Month 36.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1933"/>
                <count group_id="O2" value="1915"/>
                <count group_id="O3" value="1841"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with albuminuria progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with albuminuria regression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Albuminuria Progression or Regression at Month 48 (Overall Cardiovascular Study)</title>
        <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline and normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
        <time_frame>Month 48</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Month 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Albuminuria Progression or Regression at Month 48 (Overall Cardiovascular Study)</title>
          <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro-albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline and normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Month 48.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="825"/>
                <count group_id="O2" value="835"/>
                <count group_id="O3" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Participants with albuminuria progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Participants with albuminuria regression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Albuminuria Progression or Regression at Month 60 (Overall Cardiovascular Study)</title>
        <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
        <time_frame>Month 60</time_frame>
        <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Month 60.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Albuminuria Progression or Regression at Month 60 (Overall Cardiovascular Study)</title>
          <description>Albuminuria progression and regression were assessed relative to the baseline albuminuria category. Progression was defined as either a change from having normal albuminuria at baseline to micro albuminuria at the respective visit, or micro-albuminuria at baseline to macro-albuminuria at the respective visit, or normal albuminuria at baseline to macro-albuminuria at the respective visit. Regression was defined as either a change from having micro-albuminuria at baseline to normal albuminuria at the respective visit, or macro-albuminuria at baseline to micro-albuminuria at the respective visit, or macro-albuminuria at baseline to normal albuminuria at the respective visit. Normal albuminuria: urine albumin to urinary creatinine ratio (UACR) &lt;30 (mg/g); Micro-albuminuria: UACR 30 and 300 (mg/g); Macro-albuminuria: UACR&gt;300 (mg/g).</description>
          <population>The analysis population included all participants who were randomized, received at least one dose of blinded study medication, had a baseline measurement, and at least one measurement for the analysis endpoint for the specified timepoint at Month 60.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="780"/>
                <count group_id="O2" value="771"/>
                <count group_id="O3" value="692"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Participants with albuminuria progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="14.7"/>
                    <measurement group_id="O3" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Participants with albuminuria regression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="14.8"/>
                    <measurement group_id="O3" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing an Adverse Event (AE) (Overall Cardiovascular Study)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all participants who were randomized and who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing an Adverse Event (AE) (Overall Cardiovascular Study)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all participants who were randomized and who received at least one dose of blinded study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.8"/>
                    <measurement group_id="O2" value="84.6"/>
                    <measurement group_id="O3" value="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <other_analysis_desc>Miettinen &amp; Nurminen method</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
            <other_analysis_desc>Miettinen &amp; Nurminen method</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing an Adverse Event (AE) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 18 weeks</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing an Adverse Event (AE) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2"/>
                    <measurement group_id="O2" value="62.4"/>
                    <measurement group_id="O3" value="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
            <other_analysis_desc>Miettinen &amp; Nurminen method</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
            <other_analysis_desc>Miettinen &amp; Nurminen method</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing an Adverse Event (AE) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 18 weeks</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing an Adverse Event (AE) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3"/>
                    <measurement group_id="O2" value="25.9"/>
                    <measurement group_id="O3" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.7</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
            <other_analysis_desc>Miettinen and Nurminen method</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>-19.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.5</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
            <other_analysis_desc>Miettinen and Nurminen method</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing an Adverse Event (AE) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 18 weeks</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing an Adverse Event (AE) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="54.9"/>
                    <measurement group_id="O3" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>20.5</ci_upper_limit>
            <other_analysis_desc>Based on Miettinen and Nurminen method</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.3</ci_lower_limit>
            <ci_upper_limit>14.2</ci_upper_limit>
            <other_analysis_desc>Miettinen and Nurminen method</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Discontinuing Study Treatment Due to An AE (Overall Cardiovascular Study)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to approximately 6 years</time_frame>
        <population>The analysis population included all participants who were randomized and who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Overall Cardiovascular Study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing Study Treatment Due to An AE (Overall Cardiovascular Study)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all participants who were randomized and who received at least one dose of blinded study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2746"/>
                <count group_id="O2" value="2747"/>
                <count group_id="O3" value="2745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Discontinuing Study Treatment Due to An AE (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 18 weeks</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing Study Treatment Due to An AE (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="3.8"/>
                    <measurement group_id="O3" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <other_analysis_desc>Miettinen &amp; Nurminen method</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in % vs Placebo</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <other_analysis_desc>Miettinen &amp; Nurminen method</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Discontinuing Study Treatment Due to An AE (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 18 weeks</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing Study Treatment Due to An AE (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Discontinuing Study Treatment Due to An AE (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to 18 weeks</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing Study Treatment Due to An AE (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, and who received at least one dose of blinded study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in the FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in the FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of blinded study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.98" lower_limit="-32.80" upper_limit="-21.17"/>
                    <measurement group_id="O2" value="-33.15" lower_limit="-38.81" upper_limit="-27.48"/>
                    <measurement group_id="O3" value="-7.74" lower_limit="-13.67" upper_limit="-1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>CLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-25.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.84</ci_lower_limit>
            <ci_upper_limit>-17.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-19.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.80</ci_lower_limit>
            <ci_upper_limit>-11.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from baseline to Week 18.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" lower_limit="-2.22" upper_limit="-1.52"/>
                    <measurement group_id="O2" value="-2.13" lower_limit="-2.47" upper_limit="-1.79"/>
                    <measurement group_id="O3" value="-0.25" lower_limit="-0.60" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.37</ci_lower_limit>
            <ci_upper_limit>-1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA model</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.12</ci_lower_limit>
            <ci_upper_limit>-1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from baseline to Week 18.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="21.1"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data imputed using the Constrained Longitudinal Data Analysis (cLDA) model fitted with fixed effects as in the primary analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model fitted with fixed effects for treatment, stratum for insulin sub-study, covariates for baseline A1C and baseline eGFR (continuous).</method_desc>
            <param_type>Adjusted Odds Ratio Relative to Placebo</param_type>
            <param_value>2.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.61</ci_lower_limit>
            <ci_upper_limit>3.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data imputed using the Constrained Longitudinal Data Analysis (cLDA) model fitted with fixed effects as in the primary analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model fitted with fixed effects for treatment, stratum for insulin sub-study, covariates for baseline A1C and baseline eGFR (continuous).</method_desc>
            <param_type>Adjusted Odds Ratio Relative to Placebo</param_type>
            <param_value>2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.64</ci_lower_limit>
            <ci_upper_limit>4.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.67" lower_limit="-4.17" upper_limit="-1.18"/>
                    <measurement group_id="O2" value="-2.12" lower_limit="-3.57" upper_limit="-0.67"/>
                    <measurement group_id="O3" value="0.20" lower_limit="-1.33" upper_limit="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>cLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.35</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>cLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-2.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.94</ci_lower_limit>
            <ci_upper_limit>-0.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>This change from baseline reflects the Week 18 DBP minus the Week 0 BBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Week 18 (Excluding Rescue Approach) (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>This change from baseline reflects the Week 18 DBP minus the Week 0 BBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of study medication, and had at least one measurement for the analysis endpoint for the specified timepoint(s) at or after Baseline.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" lower_limit="-1.72" upper_limit="-0.00"/>
                    <measurement group_id="O2" value="-0.64" lower_limit="-1.47" upper_limit="0.20"/>
                    <measurement group_id="O3" value="-0.26" lower_limit="-1.14" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.533</p_value>
            <method>cLDA model</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.326</p_value>
            <method>cLDA model</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.81</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Insulin Dose for Participants Receiving Insulin at Baseline - (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>Baseline reflects Week 0 insulin dose.</description>
        <time_frame>Baseline</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, and received insulin at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Insulin Dose for Participants Receiving Insulin at Baseline - (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>Baseline reflects Week 0 insulin dose.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, and received insulin at baseline.</population>
          <units>Unit/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.76" spread="44.15"/>
                    <measurement group_id="O2" value="67.29" spread="41.23"/>
                    <measurement group_id="O3" value="73.20" spread="49.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at Week 18 in Insulin Dose for Participants Receiving Insulin at Baseline - Including Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
        <description>This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a decrease in insulin dose. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Including rescue&quot;, included data following the initiation of rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of study medication and had measurements of the analysis endpoint for the specified timepoint(s) both at Baseline and Week 18, and received insulin at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Insulin +/- Metformin Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 18 in Insulin Dose for Participants Receiving Insulin at Baseline - Including Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study)</title>
          <description>This change from baseline reflects the Week 18 insulin dose minus the Week 0 insulin dose. A negative number indicates a decrease in insulin dose. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Including rescue&quot;, included data following the initiation of rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Insulin +/- Metformin Glycemic Sub-study, received at least one dose of study medication and had measurements of the analysis endpoint for the specified timepoint(s) both at Baseline and Week 18, and received insulin at baseline.</population>
          <units>Unit/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="366"/>
                <count group_id="O3" value="346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="10.14"/>
                    <measurement group_id="O2" value="-2.14" spread="10.23"/>
                    <measurement group_id="O3" value="-0.29" spread="11.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
        <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
          <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from baseline to Week 18.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.28" lower_limit="-39.44" upper_limit="-17.12"/>
                    <measurement group_id="O2" value="-26.97" lower_limit="-38.51" upper_limit="-15.44"/>
                    <measurement group_id="O3" value="-14.76" lower_limit="-26.43" upper_limit="-3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-12.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.03</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.068</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-13.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.06</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
        <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
          <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from baseline to Week 18.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" lower_limit="-2.61" upper_limit="-0.89"/>
                    <measurement group_id="O2" value="-1.20" lower_limit="-2.09" upper_limit="-0.31"/>
                    <measurement group_id="O3" value="-0.68" lower_limit="-1.60" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.418</p_value>
            <method>cLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.79</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>cLDA model</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.32</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data imputed using the Constrained Longitudinal Data Analysis (cLDA) model fitted with fixed effects as in the primary analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.460</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR (continuous).</method_desc>
            <param_type>Odds ratio relative to placebo</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>4.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data imputed using the Constrained Longitudinal Data Analysis (cLDA) model fitted with fixed effects as in the primary analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.335</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR (continuous).</method_desc>
            <param_type>Odds ratio relative to placebo</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>4.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
        <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
          <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" lower_limit="-4.06" upper_limit="2.63"/>
                    <measurement group_id="O2" value="-0.80" lower_limit="-4.23" upper_limit="2.63"/>
                    <measurement group_id="O3" value="-3.53" lower_limit="-7.03" upper_limit="-0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.255</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>2.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.00</ci_lower_limit>
            <ci_upper_limit>7.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.235</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>2.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.85</ci_lower_limit>
            <ci_upper_limit>7.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
        <description>This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Sulfonylurea Monotherapy Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study)</title>
          <description>This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Sulfonylurea Monotherapy Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" lower_limit="-3.24" upper_limit="0.88"/>
                    <measurement group_id="O2" value="-0.93" lower_limit="-3.05" upper_limit="1.18"/>
                    <measurement group_id="O3" value="-2.91" lower_limit="-5.06" upper_limit="-0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.178</p_value>
            <method>cLDA model</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>1.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>4.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.230</p_value>
            <method>cLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR, stratum (insulin alone or insulin + metformin), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>4.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
        <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
          <description>FPG was analyzed after an overnight fast. This change from baseline reflects the Week 18 FPG minus the Week 0 FPG. A negative number indicates a reduction in FPG. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.28" lower_limit="-43.05" upper_limit="-27.50"/>
                    <measurement group_id="O2" value="-36.18" lower_limit="-43.36" upper_limit="-28.99"/>
                    <measurement group_id="O3" value="-4.81" lower_limit="-12.10" upper_limit="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>CLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-31.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.68</ci_lower_limit>
            <ci_upper_limit>-22.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>cLDA model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-30.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.23</ci_lower_limit>
            <ci_upper_limit>-20.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
        <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
          <description>This change from baseline reflects the Week 18 body weight minus the Week 0 body weight. A negative number indicates a reduction in body weight. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" lower_limit="-2.58" upper_limit="-1.50"/>
                    <measurement group_id="O2" value="-2.41" lower_limit="-2.91" upper_limit="-1.91"/>
                    <measurement group_id="O3" value="-0.47" lower_limit="-0.97" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-1.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.65</ci_lower_limit>
            <ci_upper_limit>-1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>cLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR (continuous), and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>-0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
        <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an A1C &lt;7% (&lt;53 mmol/Mol) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
          <description>A1C is a blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from baseline to Week 18.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="32.7"/>
                    <measurement group_id="O3" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data imputed using the cLDA model fitted with fixed effects as in the primary analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR (continuous).</method_desc>
            <param_type>Adjusted odds ratio relative to placebo</param_type>
            <param_value>4.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.00</ci_lower_limit>
            <ci_upper_limit>8.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data imputed using the cLDA model fitted with fixed effects as in the primary analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR (continuous).</method_desc>
            <param_type>Adjusted odds ratio relative to placebo</param_type>
            <param_value>5.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.86</ci_lower_limit>
            <ci_upper_limit>12.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
        <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
          <description>This change from baseline reflects the Week 18 SBP minus the Week 0 SBP. A negative number indicates a reduction in SBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" lower_limit="-4.78" upper_limit="0.25"/>
                    <measurement group_id="O2" value="-1.54" lower_limit="-3.85" upper_limit="0.77"/>
                    <measurement group_id="O3" value="-0.70" lower_limit="-3.04" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.597</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.00</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.351</p_value>
            <method>cLDA</method>
            <method_desc>The model had fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.87</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
        <description>This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
        <time_frame>Baseline and Week 18</time_frame>
        <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Metformin With Sulfonylurea Glycemic Sub-study)</title>
            <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Diastolic Blood (DBP) Pressure at Week 18 (Excluding Rescue Approach) (Metformin With Sulfonylurea Add-on Glycemic Sub-study)</title>
          <description>This change from baseline reflects the Week 18 DBP minus the Week 0 DBP. A negative number indicates a reduction in DBP. Participants who met glycemic rescue criteria received glycemic rescue medication. &quot;Excluding Rescue&quot; excluded all data following the initiation of rescue in order to avoid the confounding influence of the rescue therapy.</description>
          <population>The analysis population included all participants who were randomized, participated in the Metformin with Sulfonylurea Glycemic Sub-study, received at least one dose of study medication and had at least one measurement of the analysis endpoint for the specified timepoint(s) at any time from Baseline to Week 18.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-1.80" upper_limit="1.21"/>
                    <measurement group_id="O2" value="-0.92" lower_limit="-2.30" upper_limit="0.46"/>
                    <measurement group_id="O3" value="-0.24" lower_limit="-1.64" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.490</p_value>
            <method>cLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.60</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.958</p_value>
            <method>cLDA</method>
            <method_desc>Model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment.</method_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.07</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overall Cardiovascular study - Up to approximately 6 years 3 Glycemic Sub-studies - Up to 18 weeks</time_frame>
      <desc>The analysis population for all-cause mortality was all randomized participants and the analysis population for adverse events was all participants who received at least one dose of blinded study medication. The Overall Cardiovascular Study had a follow-up of approximately 6 years whereas the glycemic sub-studies had an 18-week follow-up time.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ertugliflozin 5 mg (Overall Cardiovascular Study)</title>
          <description>Ertugliflozin 5 mg, administered orally, once daily, for up to approximately 6 years</description>
        </group>
        <group group_id="E2">
          <title>Ertugliflozin 15 mg (Overall Cardiovascular Study)</title>
          <description>Ertugliflozin 15 mg, administered orally, once daily, for up to approximately 6 years</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Overall Cardiovascular Study)</title>
          <description>Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years</description>
        </group>
        <group group_id="E4">
          <title>Ertugliflozin 5 mg (Insulin +/- Metformin Sub-study)</title>
          <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
        </group>
        <group group_id="E5">
          <title>Ertugliflozin 15 mg (Insulin +/- Metformin Glycemic Sub-study)</title>
          <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
        </group>
        <group group_id="E6">
          <title>Placebo (Insulin +/- Metformin Glycemic Sub-study)</title>
          <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
        </group>
        <group group_id="E7">
          <title>Ertugliflozin 5 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)</title>
          <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
        </group>
        <group group_id="E8">
          <title>Ertugliflozin 15 mg (Sulfonylurea Monotherapy Glycemic Sub-Study)</title>
          <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
        </group>
        <group group_id="E9">
          <title>Placebo (Sulfonylurea Monotherapy Glycemic Sub-Study)</title>
          <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
        </group>
        <group group_id="E10">
          <title>Ertugliflozin 5 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
          <description>Ertugliflozin 5 mg, administered orally, once daily, for up to 18 weeks</description>
        </group>
        <group group_id="E11">
          <title>Ertugliflozin 15 mg (Metformin With Sulfonylurea Glycemic Sub-study)</title>
          <description>Ertugliflozin 15 mg, administered orally, once daily, for up to 18 weeks</description>
        </group>
        <group group_id="E12">
          <title>Placebo (Metformin With Sulfonylurea Glycemic Sub-study)</title>
          <description>Matching placebo to ertugliflozin administered orally, once daily, for up to 18 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="2746"/>
                <counts group_id="E2" subjects_affected="233" subjects_at_risk="2747"/>
                <counts group_id="E3" subjects_affected="247" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="958" subjects_at_risk="2746"/>
                <counts group_id="E2" subjects_affected="937" subjects_at_risk="2747"/>
                <counts group_id="E3" subjects_affected="990" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="347"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Blood loss anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2746"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2747"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="61" subjects_affected="52" subjects_at_risk="2746"/>
                <counts group_id="E2" events="83" subjects_affected="76" subjects_at_risk="2747"/>
                <counts group_id="E3" events="80" subjects_affected="73" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="39" subjects_affected="38" subjects_at_risk="2746"/>
                <counts group_id="E2" events="48" subjects_affected="42" subjects_at_risk="2747"/>
                <counts group_id="E3" events="54" subjects_affected="49" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="92" subjects_affected="74" subjects_at_risk="2746"/>
                <counts group_id="E2" events="78" subjects_affected="71" subjects_at_risk="2747"/>
                <counts group_id="E3" events="106" subjects_affected="89" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Anginal equivalent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="2746"/>
                <counts group_id="E2" events="38" subjects_affected="31" subjects_at_risk="2747"/>
                <counts group_id="E3" events="40" subjects_affected="37" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="2746"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2747"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2746"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="2747"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="39" subjects_affected="35" subjects_at_risk="2746"/>
                <counts group_id="E2" events="36" subjects_affected="34" subjects_at_risk="2747"/>
                <counts group_id="E3" events="58" subjects_affected="43" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2746"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2747"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="2746"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="2747"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="2746"/>
                <counts group_id="E2" events="37" subjects_affected="28" subjects_at_risk="2747"/>
                <counts group_id="E3" events="42" subjects_affected="35" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chronic left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="43" subjects_affected="35" subjects_at_risk="2746"/>
                <counts group_id="E2" events="36" subjects_affected="34" subjects_at_risk="2747"/>
                <counts group_id="E3" events="42" subjects_affected="38" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="2746"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="2747"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary ostial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="2746"/>
                <counts group_id="E2" events="52" subjects_affected="49" subjects_at_risk="2747"/>
                <counts group_id="E3" events="41" subjects_affected="37" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="2746"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="2747"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nodal arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Systolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="2747"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="2746"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="2747"/>
                <counts group_id="E3" events="22" subjects_affected="17" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic retinal oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rhegmatogenous retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tractional retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vitreoretinal traction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vitreous adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Buccal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2746"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2747"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mesenteric panniculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatic duct dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="2746"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Proctitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Strangulated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Catheter site phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="2746"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="2747"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="2746"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="2747"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="2745"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hanging</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="2746"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="2747"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Physical deconditioning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholangitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2747"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2747"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholelithiasis obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gallbladder necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gallbladder rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Post cholecystectomy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Abscess of salivary gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Actinomycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Amoebic colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Aspergilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2747"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="2746"/>
                <counts group_id="E2" events="33" subjects_affected="31" subjects_at_risk="2747"/>
                <counts group_id="E3" events="26" subjects_affected="21" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Endotoxic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="2746"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="2747"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gas gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Groin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Infective thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metapneumovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="2746"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="2747"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paraspinal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Perihepatic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="58" subjects_affected="51" subjects_at_risk="2746"/>
                <counts group_id="E2" events="48" subjects_affected="46" subjects_at_risk="2747"/>
                <counts group_id="E3" events="49" subjects_affected="45" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonia parainfluenzae viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="2746"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="2747"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Septic encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="2747"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Spinal cord infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tropical ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tuberculosis of eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="2746"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="2747"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Wound infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arterial bypass occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arterial bypass stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arterial bypass thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Confusion postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Coronary vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ear canal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Epiphyseal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Eye contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Foreign body in respiratory tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Injury corneal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Median nerve injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nerve root injury cervical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Osteoradionecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paranasal sinus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Periprocedural myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Post procedural myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Postpericardiotomy syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="13" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tooth injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Traumatic lung injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vascular access site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vascular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Antipsychotic drug level increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiometabolic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="2746"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="2747"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hyperosmolar state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="2746"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2747"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Insulin-requiring type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Connective tissue inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Joint contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Loose body in joint</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Osteitis deformans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="2746"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="2747"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Undifferentiated connective tissue disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Acute promyelocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atypical fibroxanthoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>B-cell small lymphocytic lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="2746"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="2747"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bone giant cell tumour malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Breast cancer stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cardiac myxoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Clear cell endometrial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ductal adenocarcinoma of pancreas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Endometrial cancer stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Glioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hair follicle tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>High-grade B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intraductal papillary-mucinous carcinoma of pancreas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Large cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Marginal zone lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mesothelioma malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastases to abdominal cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastatic lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neoplasm of orbit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour of the lung metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oesophageal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Oral neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Papillary renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paranasal sinus benign neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paranasal sinus neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Penis carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="2746"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="2747"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="2746"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="2747"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Testicular cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tongue cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tumour of ampulla of Vater</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vulval cancer stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="2746"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="2747"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebellar stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebral circulatory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2746"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebral small vessel ischaemic disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebral venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="2746"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="2747"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="2745"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="370"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chronic inflammatory demyelinating polyradiculoneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Essential tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hemiparaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="2746"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="2747"/>
                <counts group_id="E3" events="45" subjects_affected="41" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mixed dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neuralgic amyotrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="2746"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="2747"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="2746"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="2747"/>
                <counts group_id="E3" events="25" subjects_affected="23" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vertebral artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Device stimulation issue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="2746"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="2747"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bladder dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Stag horn calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired hydrocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="2746"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="2747"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Orchitis noninfective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Prostatic dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Testicular mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2746"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2747"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Asthma-chronic obstructive pulmonary disease overlap syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="2746"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="2747"/>
                <counts group_id="E3" events="19" subjects_affected="14" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2746"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2747"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pulmonary granuloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2746"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2747"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="2746"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2747"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Ischaemic skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Atrial appendage closure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Brachiocephalic artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Haemorrhagic vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Iliac artery rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="2746"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="2747"/>
                <counts group_id="E3" events="25" subjects_affected="22" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="2747"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2746"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="2746"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="2747"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2746"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="2747"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Subclavian artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2746"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2746"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2747"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2745"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="370"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1405" subjects_at_risk="2746"/>
                <counts group_id="E2" subjects_affected="1389" subjects_at_risk="2747"/>
                <counts group_id="E3" subjects_affected="1395" subjects_at_risk="2745"/>
                <counts group_id="E4" subjects_affected="127" subjects_at_risk="348"/>
                <counts group_id="E5" subjects_affected="144" subjects_at_risk="370"/>
                <counts group_id="E6" subjects_affected="135" subjects_at_risk="347"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E10" subjects_affected="24" subjects_at_risk="100"/>
                <counts group_id="E11" subjects_affected="32" subjects_at_risk="113"/>
                <counts group_id="E12" subjects_affected="26" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="163" subjects_affected="132" subjects_at_risk="2746"/>
                <counts group_id="E2" events="161" subjects_affected="138" subjects_at_risk="2747"/>
                <counts group_id="E3" events="153" subjects_affected="126" subjects_at_risk="2745"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="348"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="370"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="249" subjects_affected="178" subjects_at_risk="2746"/>
                <counts group_id="E2" events="272" subjects_affected="204" subjects_at_risk="2747"/>
                <counts group_id="E3" events="244" subjects_affected="186" subjects_at_risk="2745"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="370"/>
                <counts group_id="E6" events="12" subjects_affected="11" subjects_at_risk="347"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="277" subjects_affected="197" subjects_at_risk="2746"/>
                <counts group_id="E2" events="257" subjects_affected="177" subjects_at_risk="2747"/>
                <counts group_id="E3" events="324" subjects_affected="203" subjects_at_risk="2745"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="348"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="370"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E12" events="4" subjects_affected="4" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="378" subjects_affected="256" subjects_at_risk="2746"/>
                <counts group_id="E2" events="354" subjects_affected="262" subjects_at_risk="2747"/>
                <counts group_id="E3" events="301" subjects_affected="211" subjects_at_risk="2745"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="348"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="370"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="347"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E11" events="5" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E12" events="4" subjects_affected="3" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="158" subjects_affected="106" subjects_at_risk="2746"/>
                <counts group_id="E2" events="201" subjects_affected="96" subjects_at_risk="2747"/>
                <counts group_id="E3" events="283" subjects_affected="178" subjects_at_risk="2745"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E5" events="13" subjects_affected="9" subjects_at_risk="370"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="347"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="10056" subjects_affected="883" subjects_at_risk="2746"/>
                <counts group_id="E2" events="9474" subjects_affected="854" subjects_at_risk="2747"/>
                <counts group_id="E3" events="11591" subjects_affected="884" subjects_at_risk="2745"/>
                <counts group_id="E4" events="400" subjects_affected="101" subjects_at_risk="348"/>
                <counts group_id="E5" events="541" subjects_affected="112" subjects_at_risk="370"/>
                <counts group_id="E6" events="559" subjects_affected="109" subjects_at_risk="347"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="23" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E11" events="110" subjects_affected="19" subjects_at_risk="113"/>
                <counts group_id="E12" events="49" subjects_affected="14" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="144" subjects_affected="133" subjects_at_risk="2746"/>
                <counts group_id="E2" events="157" subjects_affected="138" subjects_at_risk="2747"/>
                <counts group_id="E3" events="160" subjects_affected="143" subjects_at_risk="2745"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="370"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="174" subjects_affected="139" subjects_at_risk="2746"/>
                <counts group_id="E2" events="179" subjects_affected="141" subjects_at_risk="2747"/>
                <counts group_id="E3" events="107" subjects_affected="89" subjects_at_risk="2745"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="348"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="370"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="347"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="218" subjects_affected="133" subjects_at_risk="2746"/>
                <counts group_id="E2" events="272" subjects_affected="148" subjects_at_risk="2747"/>
                <counts group_id="E3" events="343" subjects_affected="168" subjects_at_risk="2745"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="370"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure to the sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, investigator agrees to delay the disclosure for an additional 60 days. Investigator will, on request, remove any previously undisclosed Confidential Information (other than the Study results themselves) before disclosure.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

